We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kura Oncology Starts Dosing Patients in Phase II CMML Study
Read MoreHide Full Article
Kura Oncology, Inc. (KURA - Free Report) announced the dosing of the first patient in a phase II study on its farnesyl transferase inhibitor, tipifarnib, for the treatment of chronic myelomonocytic leukemia (CMML).
Shares of Kura have outperformed the Zacks classified Medical-Biomedical and Genetics industry, with the stock surging 10.7% in the past one year while the industry witnessed a drop of 8.7%.
The study will enroll about 20 patients with CMML and evaluate anti-tumor activity of tipifarnib with regard to the overall response rate. In addition, patient samples will be analyzed for the presence or absence of various biomarkers possibly relevant to the activity of tipifarnib.
We are encouraged by Kura’s progress with tipifarnib. According to the information provided by the company in its press release, CMML is projected to have an annual incidence of approximately 1,400 patients in the U.S. and is usually associated with poor prognosis due to limited treatment options, with only a 29% survival rate after three years of diagnosis.
Kura is evaluating tipifarnib in several other phase II studies for the treatment of HRAS mutant squamous cell head and neck cancer, lower-risk myelodysplastic syndromes and peripheral T-cell lymphoma.
Considering that Kura has no approved product in its portfolio at the moment and tipifarnib is its lead pipeline candidate, we expect investor focus to remain on further updates pertaining to its development.
Zacks Rank & Stocks to Consider
Kura currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in this industry include Anika Therapeutics, Inc. (ANIK - Free Report) , Acorda Therapeutics, Inc. and Sunesis Pharmaceuticals, Inc. . While Anika and Sunesis are Zacks Rank #1 (Strong Buy) stocks, Acorda carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.3% in the past one year.
Sunesis’ loss estimates narrowed from $2.57 to $2.42 for 2016 and from $2.16 to $1.85 for 2017, over the last 60 days. The company recorded a positive surprise thrice in the trailing four quarters, the average being 0.54%.
Acorda’s loss estimates narrowed from 82 cents to 40 cents for 2017 over the last 60 days. The company recorded an average positive surprise of 168.27%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kura Oncology Starts Dosing Patients in Phase II CMML Study
Kura Oncology, Inc. (KURA - Free Report) announced the dosing of the first patient in a phase II study on its farnesyl transferase inhibitor, tipifarnib, for the treatment of chronic myelomonocytic leukemia (CMML).
Shares of Kura have outperformed the Zacks classified Medical-Biomedical and Genetics industry, with the stock surging 10.7% in the past one year while the industry witnessed a drop of 8.7%.
The study will enroll about 20 patients with CMML and evaluate anti-tumor activity of tipifarnib with regard to the overall response rate. In addition, patient samples will be analyzed for the presence or absence of various biomarkers possibly relevant to the activity of tipifarnib.
We are encouraged by Kura’s progress with tipifarnib. According to the information provided by the company in its press release, CMML is projected to have an annual incidence of approximately 1,400 patients in the U.S. and is usually associated with poor prognosis due to limited treatment options, with only a 29% survival rate after three years of diagnosis.
Kura is evaluating tipifarnib in several other phase II studies for the treatment of HRAS mutant squamous cell head and neck cancer, lower-risk myelodysplastic syndromes and peripheral T-cell lymphoma.
Considering that Kura has no approved product in its portfolio at the moment and tipifarnib is its lead pipeline candidate, we expect investor focus to remain on further updates pertaining to its development.
Zacks Rank & Stocks to Consider
Kura currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in this industry include Anika Therapeutics, Inc. (ANIK - Free Report) , Acorda Therapeutics, Inc. and Sunesis Pharmaceuticals, Inc. . While Anika and Sunesis are Zacks Rank #1 (Strong Buy) stocks, Acorda carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.3% in the past one year.
Sunesis’ loss estimates narrowed from $2.57 to $2.42 for 2016 and from $2.16 to $1.85 for 2017, over the last 60 days. The company recorded a positive surprise thrice in the trailing four quarters, the average being 0.54%.
Acorda’s loss estimates narrowed from 82 cents to 40 cents for 2017 over the last 60 days. The company recorded an average positive surprise of 168.27%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>